Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprorelin 3M in Central Precocious Puberty
NCT05341115Phase 4Completed
- Sponsor
- Takeda
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by Takeda. Primary endpoint: Percentage of Participants With Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at 24 weeks. Started Mar 2023; status: completed.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on NCT05341115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341115.